Amneal Pharmaceuticals, Inc. (AMRX) P/E Ratio History
UndervaluedTrading at 76.9x vs 5Y avg 198.3x · 67th percentile · Below historical baseline · Data 2017–2026
Loading P/E history...
P/E Ratio Analysis
As of July 7, 2026, Amneal Pharmaceuticals, Inc. (AMRX) trades at a price-to-earnings ratio of 76.9x, with a stock price of $16.92 and trailing twelve-month earnings per share of $0.37.
The current P/E is 61% below its 5-year average of 198.3x. Over the past five years, AMRX's P/E has ranged from a low of 7.4x to a high of 1225.8x, placing the current valuation at the 67th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.5x, AMRX trades at a 227% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 199.4x.
Relative to the broader market, AMRX commands a significant premium over the S&P 500 median P/E of 25.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AMRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AMRX P/E vs Peers
Complex generics and injectables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 27.9 | - | +183% | |
| $1B | 28.7 | 3.84 | +1883%Best | |
| $94B | 20.4 | - | +49% | |
| $56B | 36.8 | - | +87% | |
| $130B | 73.4 | - | -62% | |
| $135B | 17.4 | - | -4% | |
| $313B | 17.4Lowest | 0.82Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AMRX Historical P/E Data (2017–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $12.43 | $0.38 | 33.0x | -83% |
| FY2025 Q4 | Dec 31 2025 | $12.60 | $0.22 | 56.1x | -72% |
| FY2025 Q3 | - | $10.01 | $0.01 | 685.6x | +246% |
| FY2025 Q2 | Jun 30 2025 | $8.09 | $0.01 | 1225.8x | +518% |
| FY2023 Q3 | Sep 30 2023 | $4.22 | $0.03 | 120.9x | -39% |
| FY2021 Q4 | Dec 31 2021 | $4.79 | $0.07 | 69.5x | -65% |
| FY2021 Q3 | - | $5.34 | $0.09 | 58.7x | -70% |
| FY2021 Q2 | Jun 30 2021 | $5.12 | $0.06 | 87.4x | -56% |
| FY2020 Q4 | - | $4.57 | $0.62 | 7.4x | -96% |
| FY2020 Q3 | Sep 30 2020 | $3.88 | $0.41 | 9.5x | -95% |
| FY2018 Q1 | Mar 31 2018 | $19.45 | $1.50 | 13.0x | -93% |
| FY2017 Q4 | Dec 31 2017 | $16.65 | $1.34 | 12.4x | -94% |
Average P/E for displayed period: 198.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
What is AMRX's P/E ratio?
Amneal Pharmaceuticals, Inc. (AMRX) trailing twelve-month P/E ratio is 76.9x, based on TTM diluted EPS of $0.37. The 5-year average P/E is 198.3x and the historical range spans 7.4x to 1225.8x.
Is AMRX stock overvalued or undervalued?
AMRX trades at 76.9x P/E, below its 5-year average of 198.3x. At the 67th percentile of its historical range (7.4x–1225.8x), the stock is priced at a discount to its own history.
Is AMRX stock expensive?
No, AMRX is not expensive on a historical basis. The current P/E of 76.9x is below the 5-year average of 198.3x and sits at the 67th percentile of its valuation range.
What is AMRX's historical P/E range?
Over the past 5 years, AMRX's P/E ratio has ranged from 7.4x to 1225.8x, with a median of 58.7x and an average of 198.3x. The current P/E of 76.9x places the stock at the 67th percentile of this range. Full historical data spans 2017–2026.
How does AMRX's P/E compare to the S&P 500?
AMRX trades at 76.9x P/E versus the S&P 500 median of 25.6x. The 200% premium to the market typically reflects higher expected earnings growth or quality.
How does AMRX's valuation compare to Healthcare peers?
Amneal Pharmaceuticals, Inc. P/E of 76.9x compares to the Healthcare sector median of 23.5x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AMRX's PEG ratio?
AMRX PEG ratio is N/A, based on a P/E of 76.9x and EPS growth of 157.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AMRX's earnings yield?
AMRX earnings yield is 1.30%, the inverse of its 76.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.